InvestorsHub Logo
Followers 2
Posts 1472
Boards Moderated 0
Alias Born 07/20/2016

Re: gajj post# 83091

Monday, 10/15/2018 3:23:33 PM

Monday, October 15, 2018 3:23:33 PM

Post# of 108192
"Chairperson and Managing Director of Biocon, Kiran Mazumdar-Shaw said, “Biocon is committed to finding solutions for women’s health issues. This partnership will enable us to develop ADXS–HPV a novel immunotherapy to combat cervical cancer in women. It is a promising technology that has the ability to suppress the tumor inside the micro-environment, and can be leveraged for developing several other novel therapeutics to address various unmet medical needs of patients in India and other emerging markets.”

I don't see any other mention of AXAL on the Biocon website. For all we know, the "partnership" could have been dropped or dissolved and no one told. Other than the initial filing to get AXAL approved in India (denied), I don't see anything else being done.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ADXS News